Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial
Authors:
- Peter J. PughPPPeter J. Pugh
- John N. WestJWJohn N. West
- Edwin J.R. van BeekEBEdwin J.R. van Beek
- T. Hugh JonesTJT. Hugh Jones
- Kevin S. ChannerKCKevin S. Channer
Open Access
- 10 August 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 27 (1) , 57-64
Abstract
Aims Chronic heart failure is associated with maladaptive and prolonged neurohormonal and pro-inflammatory cytokine activation causing a metabolic shift favouring catabolism, vasodilator incapacity, and loss of skeletal muscle bulk and function. In men, androgens are important determinants of anabolic function and physical strength and also possess anti-inflammatory and vasodilatory properties. Methods and results We conducted a randomized, double-blind, placebo-controlled parallel trial of testosterone replacement therapy (5 mg Androderm®) at physiological doses in 76 men (mean±SD, age 64±9.9) with heart failure (ejection fraction 32.5±11%) over a maximum follow-up period of 12 months. The primary endpoint was functional capacity as assessed by the incremental shuttle walk test (ISWT). At baseline, 18 (24%) had serum testosterone below the normal range and bioavailable testosterone correlated with distance walked on the initial ISWT (r=0.3, P=0.01). Exercise capacity significantly improved with testosterone therapy compared with placebo over the full study period (mean change +25±15 m) corresponding to a 15±11% improvement from baseline (P=0.006 ANOVA). Symptoms improved by at least one functional class on testosterone in 13 (35%) vs. 3 (8%) on placebo (P=0.01). No significant changes were found in handgrip strength, skeletal muscle bulk by cross-sectional computed tomography, or in tumour necrosis factor levels. Testosterone therapy was safe with no excess of adverse events although the patch preparation was not well tolerated by the study patients. Conclusion Testosterone replacement therapy improves functional capacity and symptoms in men with moderately severe heart failure.Keywords
This publication has 38 references indexed in Scilit:
- The Effect of Testosterone Replacement on Endogenous Inflammatory Cytokines and Lipid Profiles in Hypogonadal MenThe Journal of Clinical Endocrinology & Metabolism, 2004
- Testosterone treatment for men with chronic heart failureHeart, 2004
- Decreasing one-year mortality and hospitalization rates for heart failure in Sweden Data from the Swedish Hospital Discharge Registry 1988 to 2000European Heart Journal, 2004
- Anabolic Androgenic Steroids Produce Dose-Dependent Increase in Left Ventricular Mass in Power Athletes, and this Effect is Potentiated by Concomitant Use of Growth HormoneInternational Journal of Sports Medicine, 2003
- How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACHInternational Journal of Cardiology, 2002
- Long-Term Trends in the Incidence of and Survival with Heart FailureNew England Journal of Medicine, 2002
- The Plasma Levels of Dehydroepiandrosterone Sulfate Are Decreased in Patients with Chronic Heart Failure in Proportion to the SeverityThe Journal of Clinical Endocrinology & Metabolism, 2000
- Epidemiology, aetiology, and prognosis of heart failureHeart, 2000
- Bioavailable Testosterone and Depressed Mood in Older Men: The Rancho Bernardo StudyThe Journal of Clinical Endocrinology & Metabolism, 1999
- Insulin Resistance in Chronic Heart Failure: Relation to Severity and Etiology of Heart FailureJACC, 1997